Alafair Biosciences earned FDA 510(k) clearance for the VersaCoat tendon protector and VersaCoat nerve protector, according to a July 30 news release.
VersaCoat is a syringe-deliverable gel that offers a protective, gliding surface to limit post-operative tethering in surgical procedures involving tendons, ligaments, skeletal muscles and peripheral nerves in patients of all ages. The gel bioresorbs without any residual.
“Post-operative scarring can lead to significant issues for patients, including ongoing pain, limited mobility, and even the need for additional surgery,” orthopedic surgeon Samuel Adams, Jr., MD, said in the release. “In my practice, I’ve seen VersaWrap consistently reduce these complications and help my patients regain mobility and comfort more quickly. What intrigues me most about VersaCoat is the ability to address larger more complex injuries with a syringe deliverable gel.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
